GLP-1 maintenance after goal weight: continue, reduce, or stop?

Reaching a goal weight does not create a universal GLP-1 stopping rule. FDA-approved semaglutide and tirzepatide weight-management products are labeled for long-term weight reduction and maintenance, while stopping is commonly followed by some regain in withdrawal studies. Tapering, extending injection intervals, or using a very small “microdose” may be discussed in individual care, but those approaches are not the same as the products’ approved maintenance schedules and do not yet have comparable evidence.¹²³

The useful decision is not simply “stay on forever or quit.” It is a maintenance plan with a named objective, exact product and schedule, evidence boundary, monitoring record, cost horizon, and response if weight, appetite, side effects, access, or health circumstances change.

Four paths are often described as one choice

“Maintenance” can refer to maintaining the medication, the weight reduction, metabolic improvements, a behavior system, or all four. Clarify which outcome matters. A scale-only plan can miss changes in blood pressure, glucose, medication needs, symptoms, strength, food intake, or body composition.

The approved labels treat maintenance as part of the indication

Current Wegovy and Zepbound labeling describes reducing excess body weight and maintaining weight reduction long term in the labeled populations.¹² The labels also set formulation-specific schedules and limitations. Zepbound’s weight-maintenance doses are once weekly; Wegovy now includes oral and injectable formulations with distinct administration rules. A weekly injection schedule cannot be converted into an occasional injection or tiny dose by dividing the marketing name.

That distinction matters because online “maintenance,” “taper,” and “microdose” packages may use different products:

• an FDA-approved product at a labeled maintenance dose;
• an approved product used at a different dose or interval;
• a compounded semaglutide or tirzepatide product;
• a vial described in syringe units without a clear milligram dose; or
• another peptide marketed by association with GLP-1 drugs.

Record the proprietary or nonproprietary name, dosage form, strength, concentration when relevant, dose in milligrams, interval, dispensing source, indication, and whether the schedule is on-label. “Half a shot” and “a few units” are not complete product descriptions.

Stopping studies show a tendency, not a personal countdown

A 2026 systematic review and nonlinear meta-regression found consistent weight rebound after GLP-1 receptor-agonist cessation across the included studies. Its primary model used six randomized trials, and the authors reported that about 60% of the weight lost during treatment was regained at one year after cessation.³ That is a pooled estimate with moderate risk of bias in much of the evidence; longer-term portions of the trajectory were modeled rather than directly observed.

Randomized withdrawal trials answer a cleaner question than anecdotes because participants who first received medication are later assigned to continue or switch to placebo. In SURMOUNT-4, participants who continued tirzepatide maintained and added to their initial loss on average, while those switched to placebo regained substantial weight over the randomized period.⁵ The comparison supports continuation as an effective group-level maintenance strategy. It does not mean everyone who stops returns to baseline, or that continued treatment prevents every regain.

Ask which evidence is being quoted. A study of abrupt withdrawal cannot establish that a slow taper works better. A trial of a specific weekly dose cannot validate an every-other-week commercial program. A group average cannot predict a single person’s timing or amount of change.

Reduced-frequency evidence is promising but early

A 2026 retrospective case series followed 30 adults who had reached a plateau on weekly semaglutide or tirzepatide and then usually moved to every-other-week dosing. Average weight and measured outcomes were maintained over roughly 36 weeks of reduced-frequency treatment.⁴ This is useful early evidence, not a replacement for a randomized comparison. There was no concurrent control group, the cohort was small and selected, schedules were not one uniform protocol, and the findings cannot establish the best interval or who can reproduce the result.

“Microdosing” is even less precise. It might mean a lower labeled dose, a non-labeled small dose, fewer injections, concentration-based splitting, or use of a compounded vial. Treat it as a marketing word until the program writes down the exact product and schedule. A very small dose is not automatically safer, effective for maintenance, or easier to measure.

The reason for changing treatment changes the safest questions

A planned transition after stable progress is different from stopping because of pregnancy planning, a contraindication, a serious adverse event, severe gastrointestinal symptoms, gallbladder or pancreatic concern, dehydration, an eating-disorder concern, surgery, cost, insurance loss, or inability to obtain the same product. The current product label and clinical team should govern time-sensitive product-specific decisions.

Separate the reason from the proposed solution:

Do not let a billing cancellation become an unplanned clinical discontinuation. A subscription, prescriber relationship, pharmacy order, and medication supply may end on different dates.

Maintenance is a measurement plan, not only a dose

Define a baseline at the point of transition: weight trend rather than one reading; waist or body-composition method if it will actually inform care; blood pressure or glucose when clinically relevant; appetite and eating pattern; strength or activity; adverse effects; current medicines; and the date, dose, and formulation. Repeat the same measurements under comparable conditions.

Set a range and response ladder before normal fluctuation becomes a crisis. A plan might distinguish a brief fluctuation, a sustained trend, recurrence of the condition being treated, and a product-specific safety concern. The response could begin with record review and follow-up, not automatically a larger dose.

Avoid building the plan around a proprietary “metabolic score” unless its inputs, validation, repeatability, and action thresholds are disclosed. If body composition is used, keep the same validated method and conditions; the DEXA, BIA, and 3D scan guide explains why results from unlike devices should not be spliced into one trend.

Price the stable state and the transition

Maintenance cost can include medication, clinical visits, laboratory work, nutrition or behavioral support, supplies, shipping, membership fees, and dose-dependent price changes. Ask whether the quoted price assumes a labeled product, a compounded product, a reduced frequency, or an introductory dose. The medical weight-loss cost guide provides a comparison unit that keeps those pieces visible.

Also price reversibility: Is there a follow-up visit after stopping? Who manages a return of symptoms? Can records transfer to another prescriber? What happens to prepaid medication or membership credits? Does the pharmacy source change when the schedule changes?

Build the maintenance record before the goal date

1. Name the continuing indication. Write what condition and outcome the medication is addressing now, not only the original goal-weight number.
2. Freeze the current product. Record brand or compounder, formulation, strength, concentration, dose, interval, lot or prescription details, and dispensing source.
3. Classify the proposed schedule. Identify whether it is a labeled maintenance dose, another labeled option, an off-label interval or dose, or discontinuation.
4. Match evidence to the proposal. Separate randomized continuation and withdrawal data from small case series, anecdotes, and product-adjacent claims.
5. Define monitoring and thresholds. Choose comparable measures, review timing, and the events that trigger reassessment, holding, resuming, or another route.
6. Assign continuity ownership. Name the prescriber, dispensing source, after-hours contact, record recipient, and plan for access or coverage changes.

The decisive question is: “What exact product and schedule are you proposing after my goal weight, is that schedule within current labeling, what evidence supports it, and which measured change would make us revise the plan?”